GESTATIONAL DIABETES

Authors
Karen L. Whalen, Pharm.D., BCPS, CDE, FAPhA
Clinical Professor
Department of Pharmacotherapy and Translational Research
University of Florida
Gainesville, Florida

James R. Taylor, Pharm.D., BCACP, CDE
Clinical Associate Professor
Department of Pharmacotherapy and Translational Research
University of Florida
Gainesville, Florida

Reviewers
Bethany L. Murphy, Pharm.D., BCACP, BC-ADM
Assistant Professor
Department of Pharmacy Practice
Union University School of Pharmacy
Jackson, Tennessee

Steve C. Burkes, Pharm.D., BCPS, CSP
Clinical Pharmacist
Department of Adult Endocrinology
Vanderbilt University Medical Center
Nashville, Tennessee

NEW PHARMACOTHERAPIES FOR TYPE 2 DIABETES

Authors
Charmaine D. Rochester-Eyeguokan, Pharm.D., CDE, BCPS, BCACP
Associate Professor
Department of Pharmacy Practice and Science
University of Maryland School of Pharmacy
Baltimore, Maryland

Roshni S. Patel, Pharm.D., BCPS
Assistant Professor
Department of Pharmacy Practice
Jefferson College of Pharmacy,
Thomas Jefferson University
Philadelphia, Pennsylvania

Reviewers
Christie A. Schumacher, Pharm.D., BCPS, BCACP, BC-ADM, CDE
Associate Professor
Department of Pharmacy Practice
Midwestern University
Downers Grove, Illinois

Judith L. Kristeller, Pharm.D., BCPS
Professor
Department of Pharmacy Practice
Wilkes University
Wilkes-Barre, Pennsylvania

The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the Endocrinology I chapters:

Anne L. Hume, Pharm.D., FCCP, BCPS
Professor of Pharmacy
Department of Pharmacy Practice
University of Rhode Island
Kingston, Rhode Island

Adjunct Professor of Family Medicine
Alpert School of Medicine at Brown University
Providence, Rhode Island
DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

Consultancies: Dana A. Brown (Wolters Kluwer, Elsevier, Pharmacy Times); Katie E. Cardone: AstraZeneca, Fresenius Medical Care); Bethany L. Murphy (Rx Prep); Charmaine D. Rochester-Eyeguokan (Maryland Board of Pharmacy)

Royalties:

Grants: Christie A. Schumacher (National Heart, Lung, and Blood Institute)

Honoraria: Elizabeth W. Blake (South Carolina Pharmacy Association); Dana A. Brown (Kaplan); Daniel R. Malcom (Boehringer-Ingelheim)

Other: Stock Ownership:

Nothing to disclose: Janna Afanasjeva; Nicholas D. Baker; Mary M. Bridgeman; Steve C. Burkes; Eric A. Dietrich; Nancy Hope Goodbar; Amy M. Henneman; Matthew D. Kostoff; Judith L. Kristeller; Maria J. Longo; Stephanie N. Martens; Melanie N. Michael; Roshni Patel; Jodi Peoples; Evgenia Prokopenko; Kayce M. Shealy; James R. Taylor; Tristan Timbrook; Karen L. Whalen; Elizabeth Wilpula

ROLE OF BPS: The Board of Pharmacy Specialties (BPS) is an autonomous division of the American Pharmacists Association (APhA). BPS is totally separate and distinct from ACCP. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. PSAP has been approved by BPS for use in BCPS recertification. For more information about the BPS recertification process, click here.

Other questions regarding recertification should be directed to:

Board of Pharmacy Specialties
2215 Constitution Avenue NW
Washington, DC 20037
(202) 429-7591